Analysts’ Opinions Are Mixed on These Healthcare Stocks: ProQR (NASDAQ: PRQR), Cytokinetics Inc. (NASDAQ: CYTK) and Zimmer Biomet Holdings (NYSE: ZBH)By Austin Angelo
Analysts have been eager to weigh in on the Healthcare sector with new ratings on ProQR (NASDAQ: PRQR), Cytokinetics Inc. (NASDAQ: CYTK) and Zimmer Biomet Holdings (NYSE: ZBH).
ProQR (NASDAQ: PRQR)
Chardan Capital analyst Madhu Kumar reiterated a Hold rating on ProQR (NASDAQ: PRQR) on October 28 and set a price target of $4.50. The company’s shares opened today at $5.40, close to its 52-week low of $3.48.
“We rate ProQR a Neutral (PT $4.50) based upon the following: We believe competition from Vertex, Nivalis and Proteostasis (all unrated) have preclinical data as good as or superior to QR-010 and/or are significantly more advanced clinically: Company Update October 28, 2016 Biotechnology & Pharmaceuticals ProQR Therapeutics NV (PRQR – $6.15 – Neutral) COMPANY NOTE Madhu Kumar, Research Analyst, Healthcare, +1-646-465-9071 [email protected] Gbola Amusa, MD, CFA , Head of Healthcare Research, +1-646-465-9024 [email protected] Sales and trading 7 a.m. to 7 p.m. ET , (646) 465-9090 Stock Data 10/27/16 Price $6.15 52 Week Range ($3.48 – $16.23) Price Target $4.50 Market Cap (mil) $143.60 Shares out (mil) 23.35 3-Mo Avg Vol 85,651 Cash per share $4.11 Total Debt (mil) $0.00 One year price history PRQR Q3 Q1 Q2 Q3 0 4 8 12 16 2016 2017 1 Year Price History for PRQR Created by BlueMatrix Please refer to important disclosure information and Regulation Analyst Certification found on pages 3 – 5 of this report. Vertex: Has standard of care in delF508 CF (Orkambi) and a broad mid/late-stage clinical pipeline focused almost exclusively on delF508 CF with comparable/superior preclinical activity to QR-010. Additionally, Vertex has established a three-year exclusive collaboration and licensing agreement with Moderna (private) to discover and develop messenger RNA (mRNA) therapeutics for CF .”
According to TipRanks.com, Kumar is ranked 0 out of 5 stars with an average return of -16.5% and a 43.3% success rate. Kumar covers the Healthcare sector, focusing on stocks such as Achillion Pharmaceuticals, Arrowhead Research, and Akari Therapeutics.
ProQR has an analyst consensus of Moderate Buy, with a price target consensus of $14.
Cytokinetics Inc. (NASDAQ: CYTK)
In a report issued on October 28, Vernon Bernardino from FBR Capital reiterated a Buy rating on Cytokinetics Inc. (NASDAQ: CYTK), with a price target of $24. The company’s shares opened today at $9.70.
“On October 27, Cytokinetics announced 3Q16 results marked by significant milestones in its clinical programs, including partner Amgen’s exercise of its option to advance CYTK’s heart failure (HF) candidate drug, Omecamtiv mecarbil (OM), into a Phase III outcomes trial, and the announcement to grant Astellas (JP 4503) an option to co-develop and co-commercialize tirasemtiv, which is in Phase III study in amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease). We think CYTK’s valuation is disconnected from the value that Amgen and Astellas place on the market potential of CYTK’s pipeline assets and the >$1 billion in milestone payments alone that CYTK could receive from their development. We look for the anticipated publication of the full results from the COSMIC-HF Phase IIb study with OM, which could be a positive catalyst in 4Q16.”
According to TipRanks.com, Bernardino is ranked 0 out of 5 stars with an average return of -21.1% and a 19.7% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as ImmunoCellular Therapeutics, Actinium Pharmaceuticals, and Conatus Pharmaceuticals.
Currently, the analyst consensus on Cytokinetics Inc. is Strong Buy and the average price target is $16, representing a 64.9% upside.
In a report issued on October 14, Cowen & Co. also reiterated a Buy rating on the stock with a $16 price target.
Zimmer Biomet Holdings (NYSE: ZBH)
According to TipRanks.com, Lichtman is a 1-star analyst with an average return of -0.9% and a 56.8% success rate. Lichtman covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp., Integra Lifesciences, and Wright Medical Group.
Currently, the analyst consensus on Zimmer Biomet Holdings is Strong Buy and the average price target is $145, representing a 36.0% upside.
In a report released today, Piper Jaffray also maintained a Buy rating on the stock.